AEON BIOPHARMA INC (AEON) Stock Price, Forecast & Analysis
USA - NYSEARCA:AEON - US00791X2099 - Common Stock
AEON Key Statistics, Chart & Performance
The current stock price of AEON is 0.9067 USD. In the past month the price decreased by -19.76%. In the past year, price decreased by -98.32%.
AEON Latest News, Press Relases and Analysis
About AEON
Company Profile
AEON Biopharma is a biopharmaceutical company focused on the development of ABP-450, a proprietary 900 kDabotulinum toxin complex, for debilitating medical conditions. The company is headquartered in Newport Beach, California and currently employs 6 full-time employees. The company went IPO on 2021-10-08. The firm is focused on developing botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions. The biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a molecular weight of 900 kDa. Its initial development programs for ABP-450 are focused on migraine, cervical dystonia and gastroparesis. Migraine is a neurological condition characterized by recurrent episodes of headaches. The firm is developing ABP-450 for the preventative treatment of migraine, which is inclusive of both chronic migraine and episodic migraine. Cervical dystonia is a neurological condition characterized by involuntary muscle contractions of the neck which may present as spasms, contractions or abnormal posture. Gastroparesis is a gastrointestinal disorder characterized by the slowing or stoppage of movement of food and liquid from the stomach to the small intestine.
Company Info
AEON BIOPHARMA INC
4040 Macarthur Boulevard, Suite 310
Newport Beach CALIFORNIA US
Employees: 6
Phone: 19492844555.0
AEON BIOPHARMA INC / AEON FAQ
Can you describe the business of AEON BIOPHARMA INC?
AEON Biopharma is a biopharmaceutical company focused on the development of ABP-450, a proprietary 900 kDabotulinum toxin complex, for debilitating medical conditions. The company is headquartered in Newport Beach, California and currently employs 6 full-time employees. The company went IPO on 2021-10-08. The firm is focused on developing botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions. The biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a molecular weight of 900 kDa. Its initial development programs for ABP-450 are focused on migraine, cervical dystonia and gastroparesis. Migraine is a neurological condition characterized by recurrent episodes of headaches. The firm is developing ABP-450 for the preventative treatment of migraine, which is inclusive of both chronic migraine and episodic migraine. Cervical dystonia is a neurological condition characterized by involuntary muscle contractions of the neck which may present as spasms, contractions or abnormal posture. Gastroparesis is a gastrointestinal disorder characterized by the slowing or stoppage of movement of food and liquid from the stomach to the small intestine.
What is the current price of AEON stock?
The current stock price of AEON is 0.9067 USD. The price decreased by -6.89% in the last trading session.
Does AEON BIOPHARMA INC pay dividends?
AEON does not pay a dividend.
How is the ChartMill rating for AEON BIOPHARMA INC?
AEON has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Would investing in AEON BIOPHARMA INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on AEON.
What is the market capitalization of AEON stock?
AEON BIOPHARMA INC (AEON) has a market capitalization of 33.69M USD. This makes AEON a Nano Cap stock.
AEON Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to AEON. When comparing the yearly performance of all stocks, AEON is a bad performer in the overall market: 92.25% of all stocks are doing better.
AEON Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to AEON. Both the profitability and financial health of AEON have multiple concerns.
AEON Financial Highlights
Over the last trailing twelve months AEON reported a non-GAAP Earnings per Share(EPS) of -5.98. The EPS increased by 99.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -14.03% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
AEON Forecast & Estimates
7 analysts have analysed AEON and the average price target is 7.34 USD. This implies a price increase of 709.97% is expected in the next year compared to the current price of 0.9067.